1 month Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR)MarketBeat
Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday. They issued an “overweight” rating and a $35.00 price target on the stock.
X